ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ocankitug

Also written as “CM326”, “CM326(formulation 1)” and “CM326(formulation 2)”.

Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.

Drug pageOcankitug: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 13, 202113 company-led studies, 5 open or runningLicense: Keymed → CSPC (JMT-Bio), Nov 2021Next primary completion: Jul 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences81 open or runningphase 2since Dec 13, 2021Apr 8, 2021none ahead
CSPC Pharmaceutical Groupits history only54 open or runningphase 3since Jan 11, 2026Mar 6, 2023Jul 1, 2027phase 2 · NCT07418736
  • Named in CSPC Pharmaceutical Group’s own pipeline as CM326, phase 3, as of Aug 20, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Keymed Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2021First study: phase 1 study in AsthmaFirst studyNCT04842201 · 44 enrolled · China
  2. Nov 2021CSPC (JMT-Bio) licensed it from KeymedLicenseMainland China, in all uses since November 2024 (respiratory diseases before) · agreed · Keymed Biosciences (HKEX announcement)
  3. Dec 9, 2021Phase 1 study in AsthmaNCT05171348 · 40 enrolled · China
  4. Dec 13, 2021Phase 2 study in Moderate-to-severe Atopic DermatitisNCT05186922 · 54 enrolled · China
  5. Mar 18, 2022Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT05324137 · 88 enrolled · China
  6. Dec 26, 20222 phase 2 studiesNCT05671445, NCT05671432
  7. Jan 27, 2023Phase 1 study in HealthyNCT05715333 · 46 enrolled · China
  8. Feb 29, 2024Named ocankitugINNProposed as its International Nonproprietary Name in WHO's List 130 · before, CM326
  9. Apr 15, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06372678 · 90 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 Keymed Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06372678Chronic Rhinosinusitis With Nasal Polyps · China2Not yet recruitingJun 30, 202690
NCT05715333Healthy · China1CompletedOct 4, 202346
NCT05671445Dermatitis, Atopic · China2UNKNOWNMar 28, 2024100
NCT05671432Moderate-to-severe Atopic Dermatitis · China2UNKNOWNDec 30, 2023240
NCT05324137Chronic Rhinosinusitis With Nasal Polyps · China2CompletedMar 29, 202488
NCT05186922Moderate-to-severe Atopic Dermatitis · China2UNKNOWNJan 202354
NCT05171348Asthma · China1CompletedOct 11, 202240
NCT04842201Asthma · China1CompletedSep 28, 202144

How it is read

Names in the registry

  • “CM326”, 10 entries
  • “CM326(formulation 1)”, 1 entry
  • “CM326(formulation 2)”, 1 entry
  • “CM326 injection”, 1 entry
  • “CM326 dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.